Position in SLS
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$6,180,439
+$3,342,220 QoQ
Shares Held
418,729
-37.6% QoQ
Ownership
0.207%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#21
of 192 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SLS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Nuveen, LLC holds $4,966,990,470 across 286 Biotechnology names. SLS ranks #101 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,019,974 | $1,259,534,587 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,081,685 | $537,305,388 | |
| 3 | EXEL |
Exelixis, Inc.
|
3,276,984 | $178,300,697 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
315,630 | $95,014,096 | |
| 5 | TGTX |
Tg Therapeutics, Inc.
|
1,625,876 | $89,325,625 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
475,231 | $89,001,259 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
365,405 | $88,051,641 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
1,970,504 | $69,736,134 |
All Filings in SLS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,180,439 | 418,729 | Shares | Defined | 2026-08-11 | |
| 2026-03-31 | $2,838,219 | 670,974 | Shares | Defined | 2026-04-30 | |
| 2025-12-31 | $3,860,332 | 1,023,961 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $1,606,634 | 997,910 | Shares | Defined | 2025-11-12 | |
| 2025-06-30 | $2,127,210 | 971,329 | Shares | Defined | 2025-08-12 | |
| No filing history on record for this holder in this stock. | ||||||